<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049629</url>
  </required_header>
  <id_info>
    <org_study_id>Lacrimera Biometry</org_study_id>
    <nct_id>NCT05049629</nct_id>
  </id_info>
  <brief_title>Effect of Chitosan-N-Acetylcysteine on IOL-power Prior to Cataract Surgery</brief_title>
  <official_title>Effect of Chitosan-N-Acetylcysteine (Lacrimera®) on IOL-power Prior to Cataract Surgery: a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vienna Institute for Research in Ocular Surgery</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vienna Institute for Research in Ocular Surgery</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Aim of this study is to evaluate the effect of treatment with Lacrimera® on calculated IOL&#xD;
      power prior to cataract surgery and on the stability of ocular surface parameters compared to&#xD;
      preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The present study seeks to investigate the effect of treatment with Lacrimera® on the&#xD;
      calculated IOL power prior to cataract surgery and on the stability of ocular surface&#xD;
      parameters compared to preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision®&#xD;
      sine).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Medical device expired&#xD;
  </why_stopped>
  <start_date type="Actual">May 12, 2021</start_date>
  <completion_date type="Actual">August 31, 2021</completion_date>
  <primary_completion_date type="Actual">August 31, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>After enrolment into the study three study visits will be scheduled. The selection of the study eye will be randomized using www.randomizer.org. The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.</intervention_model_description>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>All study-related measurements will be performed by a masked observer.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Spherical and toric IOL power</measure>
    <time_frame>1 hour</time_frame>
    <description>Spherical and toric IOL power selected at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Spherical and toric IOL power</measure>
    <time_frame>2 weeks</time_frame>
    <description>Spherical and toric IOL power selected at the 2 weeks visit</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Difference in spherical and toric IOL power</measure>
    <time_frame>2 weeks</time_frame>
    <description>Difference in spherical and toric IOL power between baseline and the 2 weeks visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Reproducibility of biometry readings</measure>
    <time_frame>2 weeks +/- 2 days</time_frame>
    <description>Reproducibility of biometry readings at each study visit (Baseline, 1 hour after Baseline, after 1 week, after 2 weeks)&#xD;
Axial length&#xD;
Keratometry readings (K1, K2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change of dry eye parameters</measure>
    <time_frame>2 weeks +/- 2 days</time_frame>
    <description>Change of dry eye parameters between baseline and 2 weeks&#xD;
BUT (fluorescein and non-invasive BUT)&#xD;
NEI grading score</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference between study and control eye</measure>
    <time_frame>2 weeks +/- 2 days</time_frame>
    <description>Difference between study and control eye (baseline and 2 weeks)&#xD;
BUT (fluorescein and non-invasive BUT)&#xD;
NEI grading score</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Eye Diseases</condition>
  <arm_group>
    <arm_group_label>Eye 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eye 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The contralateral eye serves as the control eye. After the baseline examination and the follow-up examination one hour later, patients will be released with a prescription of one drop of Lacrimera® into the study eye per day in the evening and with one drop of single-use preservative-free hyaluronic acid containing eye drops (Hylo-Vision® sine) into the control eye three times a day for 14 consecutive days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Lacrimera</intervention_name>
    <description>A new preservative-free formulation of eye drops consists of a novel biopolymer, chitosan-N-acetylcysteine (C-NAC; Lacrimera®, Croma-Pharma GmbH, Leobendorf, Austria), which electrostatically binds to the mucine layer of the tear film forming a glycocalyx-like structure.</description>
    <arm_group_label>Eye 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Hylo-Vision</intervention_name>
    <description>Preservative-free, Hyaluronic-acid containing eyedrops (Hylo-Vision® sine)</description>
    <arm_group_label>Eye 2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age older than 18 years&#xD;
&#xD;
          -  Corneal staining (marked to severe; NEI grading scale &gt;=10)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Usage of eye drops other than lubricants (e.g. antibiotics, steroids, cyclosporin-A)&#xD;
&#xD;
          -  Usage of systemic antibiotic therapy 7&#xD;
&#xD;
          -  Any pathology of the ocular surface except dry eye disease (e.g. corneal scarring,&#xD;
             cornea ectasia)&#xD;
&#xD;
          -  Ocular surgery within prior 3 months&#xD;
&#xD;
          -  Preceding refractive surgery (e.g. LASIK)&#xD;
&#xD;
          -  Ocular injury within prior 3 months&#xD;
&#xD;
          -  Ocular herpes of eye or eyelid within prior 3 months&#xD;
&#xD;
          -  Active ocular infection&#xD;
&#xD;
          -  Active ocular inflammation or history of chronic, recurrent ocular inflammation within&#xD;
             prior 3 months&#xD;
&#xD;
          -  Eyelid abnormalities that affect lid function&#xD;
&#xD;
          -  Ocular surface abnormality that may compromise corneal integrity&#xD;
&#xD;
          -  Pregnancy and nursing women (in women of childbearing age a pregnancy test will be&#xD;
             performed before inclusion into the study)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Findl, PrimUnivPrDr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vienna Institute for Research in Ocular Surgery</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vienna Institute for Research in Ocular Surgery</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 1, 2021</study_first_submitted>
  <study_first_submitted_qc>September 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 17, 2021</last_update_submitted>
  <last_update_submitted_qc>September 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vienna Institute for Research in Ocular Surgery</investigator_affiliation>
    <investigator_full_name>Prim. Prof. Dr. Oliver Findl, MBA</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

